Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes

Antonio E. Pontiroli, Anna De Pasqua, Roberto Colombo, Camillo Ricordi, Guido Pozza

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The aim of the present paper was to evaluate the prevalence of the chlorpropamide-alcohol-flush (CPAF) in patients with type 2 and with type 1 diabetes. Ninety-seven patients with type 2 diabetes and 33 with type 1 diabetes drank 40 ml vermouth 12 h after placebo and again 12 h after 1 tablet of chlorpropamide (250 mg) or 12 h after the last of repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days). Skin temperature was recorded in all patients by a thermocouple probe connected to the left cheek. In 47 patients serum concentrations of chlorpropamide and of its metabolite CBSU were also determined. The prevalence of CPAF was similar in type 1 and type 2 diabetes, was greater in women than in men, and was significantly greater after repeated administrations than after one single administration of chlorpropamide. The increase of skin temperature during a 30-min period was significantly higher in patients with CPAF than in patients without CPAF. Serum concentrations of chlorpropamide and of its metabolite CBSU were more elevated after 4 than after 1 tablet of chlorpropamide, but were not significantly different in patients with and without CPAF. These data indicate that both genetic factors and the amount of chlorpropamide used affect the appearance of CPAF. To assess the possible role of serotonin and of dopamine in the CPAF, some patients with CPAF were tested again after treatment with metergoline, an antiserotonin agent, or with bromocriptine, a dopamine-agonist. Neither drug influenced the CPAF, indicating that the two neurotransmitters are not involved in the CPAF.

Original languageEnglish
Pages (from-to)116-123
Number of pages8
JournalActa Diabetologica Latina
Volume20
Issue number2
DOIs
Publication statusPublished - Jun 1983

Fingerprint

Chlorpropamide
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Alcohols
Skin Temperature
Tablets
Metergoline

Keywords

  • Bromocriptine
  • Chlorpropamide
  • Chlorpropamide-alcohol-flush
  • Flushing
  • Metergoline
  • Skin temperature
  • Temperature sensors
  • Vermouth

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes. / Pontiroli, Antonio E.; De Pasqua, Anna; Colombo, Roberto; Ricordi, Camillo; Pozza, Guido.

In: Acta Diabetologica Latina, Vol. 20, No. 2, 06.1983, p. 116-123.

Research output: Contribution to journalArticle

Pontiroli, Antonio E. ; De Pasqua, Anna ; Colombo, Roberto ; Ricordi, Camillo ; Pozza, Guido. / Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes. In: Acta Diabetologica Latina. 1983 ; Vol. 20, No. 2. pp. 116-123.
@article{e9786498342041928e9a71275c0b751f,
title = "Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes",
abstract = "The aim of the present paper was to evaluate the prevalence of the chlorpropamide-alcohol-flush (CPAF) in patients with type 2 and with type 1 diabetes. Ninety-seven patients with type 2 diabetes and 33 with type 1 diabetes drank 40 ml vermouth 12 h after placebo and again 12 h after 1 tablet of chlorpropamide (250 mg) or 12 h after the last of repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days). Skin temperature was recorded in all patients by a thermocouple probe connected to the left cheek. In 47 patients serum concentrations of chlorpropamide and of its metabolite CBSU were also determined. The prevalence of CPAF was similar in type 1 and type 2 diabetes, was greater in women than in men, and was significantly greater after repeated administrations than after one single administration of chlorpropamide. The increase of skin temperature during a 30-min period was significantly higher in patients with CPAF than in patients without CPAF. Serum concentrations of chlorpropamide and of its metabolite CBSU were more elevated after 4 than after 1 tablet of chlorpropamide, but were not significantly different in patients with and without CPAF. These data indicate that both genetic factors and the amount of chlorpropamide used affect the appearance of CPAF. To assess the possible role of serotonin and of dopamine in the CPAF, some patients with CPAF were tested again after treatment with metergoline, an antiserotonin agent, or with bromocriptine, a dopamine-agonist. Neither drug influenced the CPAF, indicating that the two neurotransmitters are not involved in the CPAF.",
keywords = "Bromocriptine, Chlorpropamide, Chlorpropamide-alcohol-flush, Flushing, Metergoline, Skin temperature, Temperature sensors, Vermouth",
author = "Pontiroli, {Antonio E.} and {De Pasqua}, Anna and Roberto Colombo and Camillo Ricordi and Guido Pozza",
year = "1983",
month = "6",
doi = "10.1007/BF02624912",
language = "English",
volume = "20",
pages = "116--123",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes

AU - Pontiroli, Antonio E.

AU - De Pasqua, Anna

AU - Colombo, Roberto

AU - Ricordi, Camillo

AU - Pozza, Guido

PY - 1983/6

Y1 - 1983/6

N2 - The aim of the present paper was to evaluate the prevalence of the chlorpropamide-alcohol-flush (CPAF) in patients with type 2 and with type 1 diabetes. Ninety-seven patients with type 2 diabetes and 33 with type 1 diabetes drank 40 ml vermouth 12 h after placebo and again 12 h after 1 tablet of chlorpropamide (250 mg) or 12 h after the last of repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days). Skin temperature was recorded in all patients by a thermocouple probe connected to the left cheek. In 47 patients serum concentrations of chlorpropamide and of its metabolite CBSU were also determined. The prevalence of CPAF was similar in type 1 and type 2 diabetes, was greater in women than in men, and was significantly greater after repeated administrations than after one single administration of chlorpropamide. The increase of skin temperature during a 30-min period was significantly higher in patients with CPAF than in patients without CPAF. Serum concentrations of chlorpropamide and of its metabolite CBSU were more elevated after 4 than after 1 tablet of chlorpropamide, but were not significantly different in patients with and without CPAF. These data indicate that both genetic factors and the amount of chlorpropamide used affect the appearance of CPAF. To assess the possible role of serotonin and of dopamine in the CPAF, some patients with CPAF were tested again after treatment with metergoline, an antiserotonin agent, or with bromocriptine, a dopamine-agonist. Neither drug influenced the CPAF, indicating that the two neurotransmitters are not involved in the CPAF.

AB - The aim of the present paper was to evaluate the prevalence of the chlorpropamide-alcohol-flush (CPAF) in patients with type 2 and with type 1 diabetes. Ninety-seven patients with type 2 diabetes and 33 with type 1 diabetes drank 40 ml vermouth 12 h after placebo and again 12 h after 1 tablet of chlorpropamide (250 mg) or 12 h after the last of repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days). Skin temperature was recorded in all patients by a thermocouple probe connected to the left cheek. In 47 patients serum concentrations of chlorpropamide and of its metabolite CBSU were also determined. The prevalence of CPAF was similar in type 1 and type 2 diabetes, was greater in women than in men, and was significantly greater after repeated administrations than after one single administration of chlorpropamide. The increase of skin temperature during a 30-min period was significantly higher in patients with CPAF than in patients without CPAF. Serum concentrations of chlorpropamide and of its metabolite CBSU were more elevated after 4 than after 1 tablet of chlorpropamide, but were not significantly different in patients with and without CPAF. These data indicate that both genetic factors and the amount of chlorpropamide used affect the appearance of CPAF. To assess the possible role of serotonin and of dopamine in the CPAF, some patients with CPAF were tested again after treatment with metergoline, an antiserotonin agent, or with bromocriptine, a dopamine-agonist. Neither drug influenced the CPAF, indicating that the two neurotransmitters are not involved in the CPAF.

KW - Bromocriptine

KW - Chlorpropamide

KW - Chlorpropamide-alcohol-flush

KW - Flushing

KW - Metergoline

KW - Skin temperature

KW - Temperature sensors

KW - Vermouth

UR - http://www.scopus.com/inward/record.url?scp=0020599444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020599444&partnerID=8YFLogxK

U2 - 10.1007/BF02624912

DO - 10.1007/BF02624912

M3 - Article

VL - 20

SP - 116

EP - 123

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 2

ER -